However, a prespecified exploratory analysis of the KEYNOTE-010 trial, comparing pembrolizumab vs. docetaxel in previously treated PD-L1 positive advanced NSCLC, reported outcomes based on PD-L1 expression in archival (n = 455) versus newly collected (N = 578) tumor samples. This evidence concerns the gene CD274 and neoplasm.